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Background: Anemia treatment in infants with advanced or chronic kidney disease
(CKD) represents an important challenge to nephrologists. The use of darbepoetin
alfa, a novel erythropoiesis stimulating agent, has largely replaced recombinant human
erythropoietin in older children and in adults with CKD. However, studies reporting the
use of darbepoetin alfa in infants below 1 year of age are rare.
Case presentation: We report the data of three infants with advanced stage kidney
failure, aged 1, 4, and 7 months, who were treated with darbepoetin alfa and followed
for 18–41 months. Hemoglobin levels increased in all three patients, reaching the target
levels of 10.7–12 g/dl by 11, 19, and 22 weeks respectively, without any documented
adverse effects. Patients younger than 1 year of age required a larger darbepoetin alfa
dosage (ranged from 1.2 to 2.9 µg/kg per month) as compared to older children. A
review of the literature found only three studies using darbepoetin alfa successfully in
such young infants, with similar dosage and clinical success.
Conclusion: In these three patients with advanced kidney disease, darbepoetin alfa was
effective in correcting anemia with no observed side effects. It reinforces its potential use
in very young patients with advanced CKD.
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BACKGROUND
Anemia in children with chronic kidney disease (CKD) is recognized as an important comorbidity
factor and is associated with growth retardation and cognitive dysfunction (1), as well as increased
cardiovascular risk (2, 3), and accelerated CKDprogression (4). Recent studies in the pediatric CKD
population have indicated an increased risk of hospitalization and death in children with anemia,
as compared to children with appropriate hemoglobin levels (5, 6).
The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI)
guidelines recommend, in dialysed and non-dialysed children with CKD, a target hemoglobin
level between 11 and 12 g/dl (7). According to the Kidney Disease Improving General Outcome
(KDIGO) guidelines, anemia in children between 1 and 2 years of age with CKD, is defined as
hemoglobin levels below 10.7 g/dl in boys and 10.8 g/dl in girls (8). It has been demonstrated
that the use of erythropoiesis stimulating agents (ESA) for anemia in children with CKD decreases
morbidity and mortality, reduces the need for blood transfusions, and improves growth (9).
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Darbepoetin alfa (Aranesp R©) is a hyperglycosylated epoetin
analog with a similar mechanism of action as recombinant
human erythropoietin (rHuEpo) and methoxy-polyethylene
glycol-epoetin beta (Mircera R©). The administration of
darbepoetin alfa can be less frequent (weekly to monthly) than
that of rHuEpo, for which the recommended administration
frequency is 2–3 times per week (10). This latter dosing schedule
can be cumbersome in infants and may lead to difficulties in
obtaining target hemoglobin levels.
During the past 10 years, darbepoetin alfa has largely replaced
rHuEpo in older children and in adults with CKD. However, data
regarding the safety and efficacy of darbepoetin alfa in infants<1
year of age with CKD are rare (11–13). We hereby describe the
successful use of darbepoetin alfa in three infants under the age
of 8 months with advanced CKD and we performed a short non-
systematic literature review regarding the use of darbepoetin alfa
in infants <1 year of age with CKD.
PATIENTS AND METHODS
Case Study
The clinical course and laboratory data of three male infants with
advanced chronic kidney disease, aged 1, 4, and 7 months at
the beginning of therapy, were retrospectively reviewed. Patients
were followed for a minimum of 18 months (patient 3) and a
maximum of 41 months (patient 1).
The baseline hemoglobin, iron, and ferritin levels were
recorded (Table 1). Hemoglobin levels were measured
before each darbepoetin alfa injection. Darbepoetin was
first administered intravenously then subcutaneously in all
patients. Target hemoglobin levels were established at 10.7–12
g/dl. All three patients were on oral iron supplement therapy
[5 mg/kg of iron (III)-hydroxide polymaltose]. Adjustments
of darbepoetin alfa dosage of ∼25% were made if hemoglobin
measurement remained below the target levels. Potential adverse
effects (hypertension, seizures, local pain or inflammation,
thrombocytosis) and unexpected reactions were all recorded
during the follow-up.
Literature Review
We searched the PubMed and Cochrane Library from the date
of their inception to September, 12, 2018, to identify articles on
darbepoetin alfa use in children aged<1 year using the keywords
“darbepoetin” AND (“infant” OR “newborn”). We retrieved 33
articles, limited to humans and published in the English language.
After reading the full text, three studies were included in our
review. From the literature and appropriately selected papers,
we also compared the pharmacology and pharmacokinetics of
darbepoetin alpha in very young children receiving the drug for
indications other than CKD.
Abbreviations: CKD, chronic kidney disease; ESA, erythropoiesis stimulating
agents; eGFR, estimated glomerular filtration rate; NKF KDOQI, National Kidney
Foundation Kidney Disease Outcomes Quality Initiative; rHuEpo, recombinant
human erythropoietin.
RESULTS
Patient 1 was a 7-month-old boy with CKD due to obstructive
uropathy, with an estimated glomerular filtration rate (eGFR)
of 30 ml/min × 1.73 m2. His anemia had been previously
treated with epoetin beta (Recormon R©) at the doses of 160
UI/kg twice a week. Despite epoetin alfa treatment associated
with oral iron (4–6 mg/kg daily) and folic acid (1–2.5 mg/kg
weekly) supplementations, adequate hemoglobin levels were not
achieved. A switch to darbepoetin alfa at a mean dosage of 0.6
µg/kg twice permonth allowed reaching hemoglobin target levels
by week 11 (Figure 1A, Table 1). Treatment was interrupted for
2 months secondary to hemoglobin values above the target levels.
It was then reintroduced at a slightly lower dose of 0.54 µg/kg
twice per month, and then at a dose of 0.94 µg/kg monthly, with
a favorable response (Tables 1, 2). After 41 months of follow-up,
the hemoglobin level was 12 g/dl (Table 2). No adverse reaction
was recorded during the treatment period.
Patient 2 was a 1-month-old newborn with severe renal failure
due to obstructive uropathy (eGFR <10 ml/min × 1.73 m2). He
was temporarily dialysed for 2 weeks during the neonatal period
because of fluid overload and severe hyponatremia. Treatment
with darbepoetin alfa was initially started at a dose of 0.8
µg/kg subcutaneously twice per month, and then increased to
a mean dose of 1 µg/kg, given at a mean interval of 2.8 weeks
(Figure 1B, Table 2) together with oral iron supplementation (5
mg/kg/d). This allowed reaching his hemoglobin target level at
week 19. After 19 months of follow-up the hemoglobin level was
11.8 g/dl. There were no adverse effect recorded during therapy.
Patient 3 was a 4-month-old infant with advanced renal
failure (eGFR <20 ml/min × 1.73 m2), secondary to obstructive
uropathy. Darbepoetin alfa treatment was started at a dose of 1
µg/kg twice a month, associated with oral iron supplementation
(5 mg/kg/d). Target hemoglobin level was reached at week 22,
with a mean dose of darbepoetin alfa of 1.1 µg/kg every other
week (Figure 1C, Table 2). After 18 months of follow-up, the
hemoglobin level was stable at 11 g/dl (Table 1). No side-effects
were recorded during follow-up. The iron stores evaluated at the
beginning of the treatment were low for all of infants. Oral iron
substitution allowed correction of iron deficit in all patients.
DISCUSSION
We report the cases of three infants aged 1–7 months with
anemia and advanced CKD who were successfully treated with
darbepoetin alfa. Although darbepoetin alfa has been effectively
used in children with CKD above the age of 1 year (14–
16), studies reporting the use of this treatment in a younger
population remain sparse. Durkan et al. (12) were the first to
demonstrate the efficacy of darbepoetin alfa in a study including
six infants with anemia due to CKD, aged 0.9–7.9 months with a
mean weight of 4 kg and creatinine levels between 126 and 340
µmol/l. This retrospective study revealed an optimal response
to treatment with darbepoetin alfa at a relatively small dose
(0.25 µg/kg/week) in three patients, but surprisingly no effect
on hemoglobin level in the three other infants with medical
complications, and this despite adjusting dosage up to 1.1
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TABLE 1 | Characteristics of patients at baseline and at the last control.
Baseline Last control
Patient Age
(months)
Hemoglobin
(g/l)
Creatinine
(µmol/l)
Iron
(µmol/l)
Ferritin
(µg/l)
Age
(months)
Hemoglobin
(g/dl)
Creatinine
(µmol/l)
Iron
(µmol/l)
Ferritin
(µg/l)
1 7 9.3 135 11.4 27 48 12.1 142 15.9 146
2 1 10.7 249 14.7 96 20 11.8 445 15.6 109
3 4 7.7 235 15.2 485 22 11.0 150 N/A N/A
FIGURE 1 | (A–C) Hemoglobin evolution in patient 1, 2, 3.
TABLE 2 | Darbepoetin alfa doses and intervals.
Before achieving Hb target At the last control
Patient Dose of
darbepoetin
(µg/kg)
Mean (SD)
Range
Interval between
doses (weeks)
Mean (SD)
Range
Dose of
darbepoetin
(µg/kg)
Interval
between doses
(weeks)
1 0.6 (0.02)
0.58–0.62
2.2 (0.44)
2–3
0.94 4
2 1.02 (0.19)
0.75–1.2
2.83 (0.98)
2–4
1.0 2
3 1.1 (0.16)
1.0–1.45
2 (0)
2
1.0 2
µg/kg/week. All infants were treated for a 20-week period at 1 to 4
week intervals between doses. In this study the hemoglobin target
was fixed at 10–11 g/dl based on NKF K/DOQI guidelines (2000)
and the recommendations of Royal College of Physicians and the
London Renal Association, which is lower than the hemoglobin
target in our study. The authors concluded that darbepoetin
alfa can be successfully administered in infants, but the dosage
needs to be tailored to each individual with varying response,
potentially depending on general medical condition.
Rijk et al. (11) reported, in a retrospective multicenter
study, 19 children on nightly intermittent peritoneal dialysis,
with a mean age of 6.8 years (range 0–17 years). All children
received darbepoetin alfa intraperitoneally for a median period
of 13 months. The initially administered dose of darbepoetin
alfa was 0.45 µg/kg/week, adjusted monthly, and reaching a
dosage of 0.63 µg/kg/week to allow keeping stable hemoglobin
levels. The following adverse effects were reported: headache,
hypertension, and peritonitis (15 episodes). The authors
concluded that intraperitoneal treatment with darbepoetin alfa
is an effective alternative to rHuEpo treatment, with less frequent
administration in children with CKD. Unfortunately, the exact
age for each individual was not described, and the exact number
of patients <1 year of age and their precise clinical outcome are
not available.
Recently, Schaefer et al. (13), in a multicenter phase IV
prospective study, reported that darbepoetin alfa to be very
effective in treating anemia. The study included 13 infants
<1 year of age with CKD. Twelve out of 13 patients were
on darbepoetin treatment at the inclusion. After enrolment,
they received darbepoetin alfa at a mean dosage of 1.7–
3.2 µg/kg/month subcutaneously or intravenously, which was
higher than doses administrated to older children (1.2–2.7
µg/kg/month for those aged 1–17 years). Darbepoetin alfa dosage
was also higher if administrated intravenously or in dialysed
patients. A significant number of adverse events (10 cases)
were reported in this age subgroup (hypertension, diarrhea
and gastroenteritis, convulsion, pyrexia, catheter-site infection,
device-related infection, and peritonitis). The mean hemoglobin
levels rose between 3 and 6 months after the beginning of the
treatment and remained stable during the follow-up of maximum
2 years (after 15 months of follow-up data were available for 6
patients younger than 1 year at the enrolment). These results
confirm the efficacy of darbepoetin alfa in correcting anemia
in infants <1 year of age with CKD. Table 3 summarizes the 3
above-mentioned studies.
Darbepoetin alfa has been used in young infants for
indications other than CKD. In a randomized placebo-controlled
study, Ohls et al. (17) showed that darbepoetin alfa was successful
inminimizing transfusion needs andmaintaining red cell mass in
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TABLE 3 | Summary of studies reporting the use of darbepoetin alfa in infants <1 year of age.
Authors/
Year of the
study
Type of the
study
No of
patients
<1 year of
age
Treatment
indication
Doses
(µg/kg
/month)
Administration
frequency
Treatment
duration/
Follow-up
Target Hb
(g/dl)
Adverse effects
(number of patients)
Durkan et al.
(12)
Retrospective
case-series
6 CKD-induced
anemia
1.0–4.8 1–4 weeks 20 weeks 10–11 Injection site pain (6)
Rijk et al. (11) Retrospective
two-center
single-arm
Not defined
(19 patients
of age range
0–17 years)
CKD-induced
anemia
1.8–6.88 1–2 weeks Range 2–40
months
(median 13.4
months)
10.9–12.8 Hypertension (3)
Headache (1)
Peritonitis (15)
Schaefer
et al. (13)
Prospective
multicenter
observational
13 CKD- induced
anemia
1.7–3.2 2x/week–q 2
weeks
Range 1–117
weeks (mean
88 weeks)
10–12 Peritonitis (1)Pyrexia (1)
Hypertension (1)
Gastroenteritis (3)
Convulsions (1)
Catheter site infection (2)
Device-related infection (1)
preterm infants <48 h of age with a birth weight of 500–1,250 g.
Preterm infants treated with darbepoetin alfa also presented
better neurocognitive outcomes at 18 to 22 months and at 3.5
to 4 years, compared to placebo treated neonates (18, 19). In
that specific group, darbepoetin alpha was given at a starting
dose of 10 µg/kg every week subcutaneously. A recent Cochrane
review (20) evaluated effectiveness of DA in low birth weight
newborns with the significative outcome on RBC transfusions
and necrotising enterocolitis during neonatal period as well as
neurodevelopment until the age of 2.
More recently, darbepoetin alfa has also been used as a
neuroprotective agent in conjunction with cooling therapy for
hypoxic-ischemic encephalopathy in neonates. Baserga et al. (21)
found darbepoetin alpha to be safe in critically ill neonates
undergoing hypothermic therapy, at doses varying between
2 and 10 µg/kg. Further studies are necessary to assess
if darbepoetin contributes to improvement of neurological
outcomes. Darbepoetin alfa has been used formany years in older
pediatric cancer patients to treat chemotherapy-induced anemia,
at a recommended dosage of 2.25 µg/kg weekly or 500 µg every
3 weeks subcutaneously (22–24). Dosage of darbepoetin alpha
seems to be similar in children with anemia secondary to CKD
or to prematurity, but experience is sparse and target hemoglobin
are different from other indication, making comparisons difficult.
In our patients we observed a satisfactory response, without any
documented adverse effects during a follow-up of 18–41 months.
Interestingly and as recently shown by Schaefer et al. (13), we
found that patients younger than 1 year of age required a larger
darbepoetin alfa dosage than older ones. In our observation the
range of darbepoetin alfa dosage varied from 1.2 to 2.9 µg/kg
per month, close to the dosage reported in Schaefer’s study (1.7–
3.2 µg/kg per month for subgroup of infants aged <1 year).
This is higher than the recently recommended weekly dosage of
0.41 µg/kg (25–75th percentiles: 0.25–0.82 µg/kg) in pediatric
patients with CKD aged 1–18 years (14).
The most frequently reported adverse effects of darbepoetin
alfa are injection site pain, fever, headache, flu-like symptoms,
hypertension, and thrombosis of vascular access, but their
frequency compared favorably to another ESA (10–14). In
children, subcutaneous injection of darbepoetin alfa has been
reported by Schmitt et al. (25) to be more painful than those of
epoetin-beta in a prospective, randomized, double-blind trial in
13 pediatric patients. In our study, we collected retrospectively
all data concerning potential adverse events. Patient 1 and 2
were treated for hypertension, which started before darbepoetin
alpha injections and was not worsen by the latter treatment. No
injection site pain occurred in our patients, mainly because all
of them received the darbepoetin intravenously. We observed
no fever, seizure, headaches. However, it should be recognized
that the short follow-up time and the very small number of
patients preclude any firm conclusion regarding adverse effects of
darbepoeitin alpha in this very young population with advanced
CKD.
In conclusion, we report our results corroborate and extend
the recent findings of Schaefer et al. (13). Prospective studies with
larger sample size and longer follow-up should be conducted, to
ensure darbepoetin alfa long lasting efficacy and the absence of
severe or new adverse effects in young infants.
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